Rheumatism Patients' COVID antibodies under the microscope

NCT ID NCT04530682

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study followed 163 people with chronic inflammatory rheumatism (like rheumatoid arthritis) who had a recent COVID-19 infection. Researchers measured their antibody levels over two years to see how immunosuppressive drugs affect antibody persistence. The goal was to better understand immune protection and guide vaccination strategies for this group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPONDYLOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 rheumatic disorder rheumatoid arthritis Spondylarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre hopsitalier universitaire de Montpellier

    Montpellier, Occitanie, 34295, France